RE:RE:RE:RE:RE:RE:RE:Montreal's Ventus TherapeuticsIf there is not enough interest in Egrifta for NASH to generate a partnership, do you really want THTX to go it alone? I'm sure big pharma has looked at it and has said, "no thanks". So why would they pursue it?
Lee430 wrote: If we did not have this potential high reward cancer platform would Thera have kept their eyes on the NASH prize and it would maybe be in PH3 by now instead of sending it to the time out chair?
Biobob wrote: I understand the frustration since I share it on a daily basis since 1998. I wprobably wont happen but we can hope a business update on October 13 delivers soemthing that makes Paul seemingly more verbal about Th1902...